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BACKGROUND: Twin anemia polycythemia sequence is a chronic (P<.001). Severe neonatal morbidity occurred in 33% (141 of 432) of
form of unbalanced fetofetal transfusion through minuscule placental
anastomoses in monochorionic twins, leading to anemia in the donor and
polycythemia in the recipient. Owing to the low incidence of twin anemia
polycythemia sequence, data on diagnosis, management, and outcome
are limited.
OBJECTIVE: This study aimed to investigate the diagnosis, manage-
ment, and outcome in a large international cohort of spontaneous twin
anemia polycythemia sequence.
STUDYDESIGN:Data from the international twin anemia polycythemia
sequence registry, retrospectively collected between 2014 and 2019,
were used for this study. A total of 17 fetal therapy centers contributed to
the data collection. The primary outcomes were perinatal mortality and
severe neonatal morbidity. Secondary outcomes included a risk factor
analysis for perinatal mortality and severe neonatal morbidity.
RESULTS: A total of 249 cases of spontaneous twin anemia poly-
cythemia sequence were included in this study, 219 (88%) of which were
diagnosed antenatally and 30 (12%) postnatally. Twin anemia poly-
cythemia sequence was diagnosed antenatally at a median gestational age
of 23.7 weeks (interquartile range, 9.7e28.8; range, 15.1e35.3).
Antenatal management included laser surgery in 39% (86 of 219),
expectant management in 23% (51 of 219), delivery in 16% (34 of 219),
intrauterine transfusion (with partial exchange transfusion) in 12% (26 of
219), selective feticide in 8% (18 of 219), and termination of pregnancy in
1% (3 of 219) of cases. Perinatal mortality rate was 15% (72 of 493) for the
total group, 22% (54 of 243) for donors, and 7% (18 of 242) for recipientsCite this article as: Tollenaar LSA, Slaghekke F, Lewi L,
et al. Spontaneous twin anemia polycythemia sequence:
diagnosis, management, and outcome in an international
cohort of 249 cases. Am J Obstet Gynecol
2020;XX:x.exex.ex.
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https://doi.org/10.1016/j.ajog.2020.07.041twins with twin anemia polycythemia sequence and was similar for donors
(32%; 63 of 196) and recipients (33%; 75 of 228) (P¼.628). Independent
risk factors for spontaneous perinatal mortality were donor status (odds
ratio, 3.8; 95% confidence interval, 1.9e7.5; P<.001), antenatal twin
anemia polycythemia sequence stage (odds ratio, 6.3; 95% confidence
interval, 1.4e27.8; P¼.016 [stage 2]; odds ratio, 9.6; 95% confidence
interval, 2.1e45.5; P¼.005 [stage 3]; odds ratio, 20.9; 95% confidence
interval, 3.0e146.4; P¼.002 [stage 4]), and gestational age at birth (odds
ratio, 0.8; 95% confidence interval, 0.7e0.9; P¼.001). Independent risk
factors for severe neonatal morbidity were antenatal twin anemia poly-
cythemia sequence stage 4 (odds ratio, 7.9; 95% confidence interval,
1.4e43.3; P¼.018) and gestational age at birth (odds ratio, 1.7; 95%
confidence interval, 1.5e2.1, P<.001).
CONCLUSION: Spontaneous twin anemia polycythemia sequence
can develop at any time in pregnancy from the beginning of the
second trimester to the end of the third trimester. Management for
twin anemia polycythemia sequence varies considerably, with laser
surgery being the most frequent intervention. Perinatal mortality and
severe neonatal morbidity were high, the former especially so in the
donor twins.
Key words: diagnosis, intrauterine transfusion, laser surgery, man-
agement, monochorionic twins, neonatal morbidity, perinatal mortality,
registry, twin anemia polycythemia sequence, twin-twin transfusion
syndromewin anemia polycythemia sequenceT (TAPS) is a chronic form of un-
balanced fetofetal transfusion through
minuscule placental anastomoses inmonochorionic twins, leading to ane-
mia in the TAPS donor and poly-
cythemia in the TAPS recipient.1 In
contrast to twin-twin transfusion syn-
drome (TTTS), TAPS develops in the
absence of twin oligohydramnios-
polyhydramnios sequence (TOPS).
TAPS can occur spontaneously in up to
5% of monochorionic twins.2 The
optimal antenatal treatment for TAPS
has yet to be determined, but options
include expectant management, pre-
term delivery, intrauterine transfusion
(IUT) with or without a partial ex-
change transfusion (PET), fetoscopicMONTH 2020 Amlaser surgery, and selective feticide.3,4
Perinatal outcome in TAPS may vary
between isolated hemoglobin differ-
ences to severe cerebral injury and
perinatal death.5,6 Because of the low
incidence of TAPS, studies investigating
perinatal outcome are limited, with
current data based on small cohort
studies. Limited knowledge on optimal
management and short- and long-term
outcomes restricts adequate parental
counseling and informed decision
making. To improve our knowledge on
TAPS, we set up the TAPS Registry, a
large international collaboration aimederican Journal of Obstetrics& Gynecology 1.e1
AJOG at a Glance
Why was this study conducted?
This study aimed to investigate the diagnosis, management, and outcome in
spontaneous twin anemia polycythemia sequence (TAPS).
Key findings
Spontaneous TAPS can develop from 15 to 35 weeks’ gestation. Perinatal mor-
tality occurred in 15% of twins with TAPS and was significantly (P< .01) higher
in donors than in recipients (22% vs 7%, respectively). Severe neonatal morbidity
occurred in 33% of the twins and was strongly predicted by high antenatal TAPS
stage and low gestational age at birth.
What does this add to what is known?
This large international study reports that spontaneous TAPS can develop across
a wide range of gestation and is associated with high rates of perinatal mortality
and severe neonatal morbidity, the former especially so in the donor twins.
Original Research OBSTETRICS ajog.orgat collecting data on diagnosis, treat-
ment, and outcome in TAPS twins.
In this study, the data from this TAPS
Registry were used as follows: (1) to
examine the characteristics of diagnosis,
management, and outcome in twins
with spontaneous TAPS, (2) to compare
the perinatal outcomes between donors
and recipients, and (3) to investigate
potential risk factors for adverse peri-
natal outcomes. To date, TAPS is
believed to be a mild form of fetofetal
transfusion pathology,7 which mainly
develops after viable gestation. We hy-
pothesize that spontaneous TAPS may
develop earlier in pregnancy and may be
associated with higher adverse outcome
rates that are currently assumed.
Methods
The TAPS Registry was established in
2014 and used a web-based registry for
anonymous data collection (www.
tapsregistry.org). Fetal therapy centers
across the world were invited to partici-
pate. Participating centers were supplied
with personal credentials to enter data of
their TAPS cases into the online registry.
Between 2014 and 2019, 17 fetal therapy
centers contributed to the retrospective
data collection (Supplemental Table 1).
Monochorionic twin pregnancies
diagnosed as having spontaneous TAPS
were eligible for this study. Cases with
postlaser TAPS (TAPS after incomplete
laser for TTTS) were excluded from this
study and are described in a separate1.e2 American Journal of Obstetrics& Gynecologystudy.8 Antenatal diagnosis for TAPSwas
based on discordant middle cerebral ar-
tery peak systolic velocity (MCA-PSV)
measurements, with an increased MCA-
PSV in the TAPS donor, suggestive of
fetal anemia, combined with a decreased
MCA-PSV measurement in the TAPS
recipient, suggestive of fetal poly-
cythemia, and without signs of TOPS.9
TAPS was staged according to Sla-
ghekke et al.9 In brief, TAPS stage 1 was
defined as an MCA-PSV of >1.5 multi-
ples of the median (MoM) in the donor
and <1.0 MoM in the recipient. Stage 2
was based on an MCA-PSV of >1.7 for
the donor, combined with an MCA-PSV
of <0.8 in the recipient. Stage 3 was
defined as cardiac compromise of the
donor (critically abnormal flow in the
umbilical artery, umbilical vein, or duc-
tus venosus). In the case of stage 4, fetal
hydrops was seen in the donor twin. In
stage 5, fetal demise in one or both twins
occurred. TAPS was diagnosed post-
natally in cases with an intertwin he-
moglobin difference of>8.0 g/dLwith at
least 1 of the following: a reticulocyte
count ratio of >1.7 or the presence of
only minuscule vascular anastomoses
(diameter of <1 mm) detected through
color-dye injection of the placenta.10,11
The following data were retrieved
from the medical records: gravidity,
parity, location of the placenta, gesta-
tional age (GA) at diagnosis, TAPS stage
at diagnosis,9 the presence of starry-sky
liver in the recipient or the difference inMONTH 2020placental echogenicity, and mode of
delivery. The following types of man-
agement were recorded: expectant
management, delivery (defined as a
delivery within 7 days after diagnosis),
IUT (PET), laser surgery, selective
feticide, and termination of pregnancy
(TOP). Because TAPS cases can be
managed according to different strate-
gies in the same pregnancy, manage-
ment group assignment was based on
the first treatment that was performed.
In addition, information on placental
color-dye injection was collected,
including the type, number, and size of
anastomoses. For perinatal outcome,
the following parameters were ob-
tained: donor or recipient status,
birthweight, hemoglobin and reticulo-
cyte values, treatment with blood
transfusion or PETat day 1, presence of
severe neonatal morbidities, and
occurrence of perinatal mortality.
The primary outcomes were peri-
natal mortality and severe neonatal
morbidity. Perinatal mortality was
defined as fetal demise or neonatal
death within 28 days after birth.
Because fetal demise is intentional in
the context of selective feticide or TOP,
a distinction is made between sponta-
neous and intended fetal demise. Severe
neonatal morbidity was a composite
measurement and defined as the pres-
ence of at least 1 of the following,
detected within 28 days after birth or
before discharge to home: respiratory
distress syndrome requiring mechanical
ventilation and surfactant, patent duc-
tus arteriosus requiring treatment,
necrotizing enterocolitis at stage 2,12
retinopathy of prematurity at stage
3,13 ischemic limb injury, or severe ce-
rebral injury. Severe cerebral injury was
diagnosed in case of 1 of the following
abnormalities were detected on cerebral
imaging: intraventricular hemorrhage
at  stage 3,14 ventricular dilatation
(including posthemorrhagic ventricular
dilatation),15 cystic periventricular leu-
komalacia at grade 2,16 porencephalic
or parenchymal cysts, arterial infarc-
tion, or other severe cerebral lesions
associated with adverse outcome. The
following parameters were determined:
reticulocyte count ratio, the presence of
TABLE 1
Baseline characteristics of spontaneous TAPS twins
Spontaneous TAPS (N¼249
pregnancies, 498 fetuses)
Gravidity 2 (1e3)
Parity 1 (0e1)
Antenatal diagnosis of TAPS 219/249 (88)
Location of placentaa
Anterior 127/236 (54)
Posterior 104/236 (44)
Other 5/236 (2)
Data are presented as n/N (%) or median (IQR).
IQR, interquartile range; TAPS, twin anemia polycythemia sequence.
a In 13 cases, position of the placenta was unknown. Other types of placental positions included partly anterior and partly
posterior (n¼2), lateral left (n¼2), and lateral right (n¼1).
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(FGR) (defined as a birthweight at less
than the 3rd or 10th percentile,
respectively17) and postnatal TAPS
stage.18 The reticulocyte count ratio was
calculated by dividing the highest
reticulocyte count (&) by the lowest
reticulocyte count (&). Reticulocyte
counts were obtained from the umbili-
cal cord blood or heel stick or venous
puncture of each twin at day 1.
Secondary outcomes included diag-
nosis- and therapy-related characteris-
tics, hematological and placental
characteristics, and a risk factor analysis
for spontaneous perinatal mortality and
severe neonatal morbidity. For the risk
factor analysis for spontaneous mortal-
ity, cases with intentional fetal demise
due to selective feticide or TOP were
excluded. The following parameters
were investigated in the univariate risk
analysis for spontaneous perinatal mor-
tality: GA at TAPS diagnosis, antenatal
TAPS stage, TAPS donor or recipient
status, type of antenatal management,
and GA at birth. For antenatal TAPS
stage, the highest antenatal TAPS stage
that was seen during pregnancy was
selected. In the case of TAPS stage 5, the
highest TAPS stage before stage 5 was
used. For the risk factor analysis for se-
vere neonatal morbidity, 2 more pa-
rameters were added: severe FGR and the
presence of postnatal TAPS.
Statistical analyses were performed
using SPSS version 25.0 (IBM, Armonk,
New York). The sample size for this
study was based on convenience. Data
are reported as meansstandard devia-
tion or as medians or interquartile
ranges (IQRs) or ranges (minimume
maximum), as appropriate. In addition,
P<.05 indicated statistical significance.
Differences between donors and re-
cipients were calculated using the paired
t test for normally distributed contin-
uous outcomes and the generalized
estimated equation module for categor-
ical outcomes. Potential risk factors were
checked for correlation using Spear-
man’s rank test (R). Correlation coeffi-
cient R of >()0.7 was considered to
indicate a strong relationship between
the factors. Potential risk factors for
perinatal mortality and severe neonatalmorbidity were studied in a univariable
logistic regression model. A multivari-
able logistic regression model was
applied to the variables that indicated
significant association in the univariable
analysis. Results are expressed as odds
ratios (ORs) with 95% confidence in-
tervals (CIs).
Results
Of the 422 TAPS cases entered in the
TAPS Registry, 249 (59%) were spon-
taneous TAPS and included in this
study, whereas 173 (41%) were post-
laser TAPS and excluded from the
study. The number of spontaneous
TAPS cases per fetal therapy center is
presented in Supplemental Table 1.
TAPS was diagnosed antenatally in 88%
(219 of 249) of the group and post-
natally in 12% (30 of 249) (Table 1).
The median GA at diagnosis was 23.7
weeks (IQR, 19.7e28.8) and ranged
widely from 15.1 to 35.3 weeks (Figure).
In antenatally detected TAPS, 39% (86
of 219) were treated with laser surgery,
24% (52 of 219) were managed expec-
tantly, 16% (34 of 219) had a delivery,
13% (26 of 219) received IUT (PET),
8% (18 of 219) were treated with se-
lective feticide, and 1% (3 of 219) un-
derwent a TOP (Table 2).
Color-dye injection of the placenta
was performed in 44% (109 of 249) of
the cases (Table 3). In total, 24% (26MONTH 2020 Amof 109) of placentas belonged to TAPS
cases treated with laser surgery and
76% (83 of 109) belonged to TAPS
cases that were not treated with laser
surgery. In placentas not treated with
laser, the median total number of
anastomoses was 3 (1e6), and 84%
(70 of 83) of the placentas indicated
arteriovenous (AV) or venoarterial
(VA) anastomosis, or both. Arterio-
arterial (AA) and venovenous (VV)
anastomoses were detected in 19% (16
of 83) and 7% (6 of 83) of the group,
respectively. In 3 TAPS cases, the
placenta demonstrated only 1 AA or
VV anastomosis at the vascular equa-
tor. A total of 7 placentas did not
indicate any anastomoses after
placental injection. Although 3 cases
had spontaneous resolution of TAPS
during pregnancy, 1 case had normal
hemoglobin values despite an ante-
natal diagnosis of TAPS, and the 3
remaining cases presented with severe
postnatal TAPS (stage 4). In total,
94% (74 of 76) of the placentas with
anastomoses indicated only minuscule
anastomoses. Residual anastomoses
were detected in 11% (3 of 26) of
placentas treated with laser. In all 3
cases, residual anastomoses were small
and the twins had evidence of ante-
natal and postnatal TAPS.
Perinatal outcomes for the total
group of TAPS twins and for donorserican Journal of Obstetrics& Gynecology 1.e3
FIGURE
Gestational age at diagnosis in twins with spontaneous TAPS
TAPS, twin anemia polycythemia sequence.
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in Table 4. The median GA at birth for
TAPS twins was 32.3 weeks (IQR,
30.1e34.9; range, 18.7e39.6). The
donors were more often severely
growth restricted than the recipients
(49% [98 of 200] vs 11% [26 of 228];
P<.001). Fetal demise occurred in 11%
(54 of 494) of the group, either
spontaneously in 5% (24 of 494) or
intended in 6% (30 of 494). The do-
nors had a higher risk for fetal demise
than the recipients, both for sponta-
neous fetal demise (8% [19 of 242] vs
2% [5 of 241]; P¼.002) and intended
fetal demise (10% [24 of 242] vs 3%
[6 of 242]; P<.001). Overall perinatal
mortality occurred in 15% (72 of 493)
of TAPS twins, in 22% (54 of 243) of
the donors and 7% (18 of 242) of the
recipients (P<.001). Spontaneous
perinatal mortality was observed in
9% (42 of 493) of the group, in 12%
(30 of 243) of the donors and in 5%
(12 of 242) of the recipients (P<.001).1.e4 American Journal of Obstetrics& GynecologyThe rate of neonatal mortality was 4%
(18 of 439) and was comparable be-
tween the donors and recipients (6%
[11 of 200] vs 3% [7 of 231], respec-
tively; P¼.159). Severe neonatal
morbidity was diagnosed in 33% (141
of 432) of TAPS twins and was similar
for donors (32%; 63 of 196) and re-
cipients (33%; 75 of 228) (P¼.628). In
twins who were diagnosed as having
TAPS at birth (43%; 108 of 249),
intertwin hemoglobin difference was
14.3 mmol/L (IQR, 11.7e17.8) and
the reticulocyte count ratio was 3.9
(IQR, 2.5e5.3). The donors needed a
blood transfusion at birth in 76% (81
of 108) and the recipients a PET in
51% (51 of 108). In twins diagnosed as
having TAPS at birth, 17% (18 of 108)
had postnatal TAPS stage 1, 28% (30
of 108) stage 2, 24% (26 of 108) stage
3, 19% (21 of 108) stage 4, and 12%
(13 of 108) stage 5.
Details on univariable and multivar-
iable risk factor analysis for perinatalMONTH 2020mortality and severe neonatal
morbidity are presented in
Supplemental Tables 2 and 3. Multi-
variable analysis indicated that donor
status (OR, 3.8; 95% CI, 1.9e7.5;
P<.001), antenatal TAPS stage (OR, 6.3;
95% CI, 1.4e27.8 [stage 2:]; P¼.016;
OR, 9.6; 95% CI, 2.1e45.5; P¼.005
[stage 3]; OR, 20.9; 95% CI, 3.0e146.4;
P¼.002 [stage 4]), and GA at birth (OR,
0.8; 95% CI, 0.7e0.9; P¼.001) were
independent risk factors for sponta-
neous perinatal mortality. For severe
neonatal morbidity, multivariable
analysis indicated that TAPS stage 4
(OR, 7.9; 95% CI, 1.4e43.3; P¼.018)
and GA at birth (OR, 1.7; 95% CI,
1.5e2.1; P<.001) were independently
associated with severe neonatal
morbidity.
Comment
Principal findings
This was a large international study
investigating management and outcome
TABLE 2
Diagnosis- and management-related characteristics
Spontaneous TAPS (N¼249
pregnancies, 498 fetuses)
GA at diagnosis (wk) 23.7 (19.7e28.8; 15.1e35.3)
TAPS stage at diagnosis
1 80/219 (37)
2 91/219 (42)
3 38/219 (17)
4 10/219 (5)
5 0/219 (0)
Highest TAPS stage during pregnancy
1 64/219 (29)
2 88/219 (40)
3 52/219 (24)
4 12/219 (6)
5 3/219 (1)
Presence of additional ultrasound markersa
Starry-sky liver (recipient) 93/200 (47)
Difference in placental echogenicity 96/220 (44)
Antenatal management
Expectant management 51/219 (23)
Deliveryb 34/219 (16)
IUT (PET) 26/219 (12)
Laser surgery 86/219 (39)
Selective feticide 18/219 (9)
Termination of pregnancy 3/219 (1)
Femalec 251/468 (53)
Cesareand 330/488 (68)
Data are presented as median (IQR) or n/N (%).
GA, gestational age; IQR, interquartile range; IUT, intrauterine transfusion; PET, partial exchange transfusion; TAPS, twin
anemia polycythemia.
a The presence of a starry-sky liver and difference in placental echogenicity was assessed in 200 and 220 cases, respectively;
b One case that had a delivery at 27 weeks’ gestation based on TAPS stage 3 was a monoamniotic twin; c In 30 fetuses,
gender is unknown. One case was a male-female pair; d In 10 fetuses, mode of delivery is unknown.
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TAPS can develop across a wide range of
gestations. Management varied consid-
erably, with fetoscopic laser surgery be-
ing the most frequent intervention. In
this cohort, perinatal outcome was poor,
particularly because of a high perinatal
mortality rate in donor twins. These
findings stress the need for increased
awareness by clinicians concerning the
severity of TAPS. Adaptation of guide-
lines to ensure early diagnosis and pro-
spective, well-controlled studies to
determine the most optimal diagnostic
criteria and management strategy are
needed.
Results
Studies investigating perinatal outcome
in TAPS are scarce, and the majority
combine outcome of spontaneous and
post-laser TAPS twins. In a recent long-
term outcome study, fetal demise
occurred in 3% and neonatal mortality
in 2% of spontaneous TAPS twins, which
is roughly comparable to the 5% and 4%
in this study, respectively.19 This study
also reported that spontaneous TAPS
donors have a 4-fold higher odds of
neurodevelopmental impairment than
recipients. This study found that TAPS
donors not only have amore detrimental
outcome in the long-term but are also at
increased risk for mortality antenatally.
In addition, almost half of the donors in
our cohort were severely growth
restricted, in contrast to 12% of re-
cipients, which might contribute to an
impaired outcome. In this cohort, GA at
birth was a strong predictor for both
perinatal mortality and severe neonatal
morbidity, indicating that prolonging
pregnancy is crucial to improve outcome
in TAPS twins. It is unclear what the best
management option in TAPS twins is. In
this study, the type of antenatal man-
agement was not a risk factor for peri-
natal mortality or severe neonatal
morbidity. An in-depth evaluation of
outcomes after different management
strategies in 370 cases with spontaneous
and post-laser TAPS is described in a
separate study.20
In line with previous smaller studies,
in this study we found that the vast
majority (94%) of TAPS placentasindicated only minuscule anastomoses.1
Our data also revealed that AA anasto-
moses do not prevent the development
of TAPS, because they were observed in
19% of TAPS placentas, which is higher
than the 11% reported before.21 More-
over, in this study we found that VV
anastomoses can also be present in TAPS
placentas.22 Of interest, there were 3
TAPS placentas that indicated only 1
minuscule AA or VV anastomosis. It isMONTH 2020 Ampostulated that these bidirectional anas-
tomoses act like an AV anastomosis
(allowing unidirectional flow) under
certain circumstances. Of note, 7 TAPS
cases had no placental anastomoses. In 3
cases, TAPS resolved during pregnancy,
likely as a result of spontaneous throm-
bosis in an AV anastomosis.23 Three
other placentas belonged to severe
postnatal TAPS cases. Possibly, deep-
hidden anastomoses were responsibleerican Journal of Obstetrics& Gynecology 1.e5
TABLE 3
Characteristics of spontaneous TAPS placentas (not treated with laser)
Injected TAPS placentas (N¼83)
Total number of anastomoses 3 (1e6)
Number of AV anastomoses 2 (1e3)
Number of VA anastomoses 1 (0e2)
Number of AA anastomoses 0 (0e0)
Number of VV anastomoses 0 (0e0)
Presence of anastomoses
Presence of AV/VA anastomoses 70/83 (84)
Presence of AA anastomoses 16/83 (19)
Presence of VV anastomoses 6/83 (7)
Type of anastomoses per placenta
No anastomoses 7/83(8)
AV (1 direction) 21/83 (25)
AVs (both directions) 34/83 (41)
AV/VA and AA 13/83 (16)
AV/VA and VV 4/83 (5)
Only AA 2/83 (2)
Only VV 1/83 (1)
AV/VA, AA, and VV 1/83 (1)
All anastomoses diameter at <1 mma 74/76 (97)
Data are presented as median (IQR) or n/N (%).
AA, arterioarterial; AV, arteriovenous; IQR, interquartile range; TAPS, twin anemia polycythemia; TTTS, twin-twin transfusion
syndrome; VA, venoarterial; VV, venovenous.
a Reported only in cases with anastomoses; the 10 cases without anastomoses were excluded.
Tollenaar et al. Spontaneous TAPS: diagnosis management and outcome in 249 cases. Am J Obstet Gynecol 2020.
Original Research OBSTETRICS ajog.orgfor the unbalanced blood flow.24 Alter-
natively, minuscule anastomoses may
not have been seen because of subopti-
mal color-dye injection, which is known
to be technically challenging in TAPS
placentas.25
Clinical implications
Until now, information regarding the
time of onset of TAPS was limited and
based mostly on small cohort studies.
To develop adequate TAPS screening
guidelines, using routine MCA-PSV
Doppler measurements, knowledge
concerning the time of onset of TAPS
is essential. Our findings indicate that
TAPS can develop from 15 weeks to 35
weeks’ gestation. Because 3 of the 4
cases detected at 15 weeks were at
stage 2 or higher, it is likely that TAPS
manifested even earlier. Currently,1.e6 American Journal of Obstetrics& Gynecologythere is no consensus on when to start
with MCA-PSV surveillances to check
for the presence of TAPS. The Inter-
national Society of Ultrasound in
Obstetrics and Gynecology twin
guideline recommends biweekly MCA-
PSV screening starting from 20 weeks’
gestation, especially in cases treated
with laser surgery for TTTS.26 The
Society for Maternal-Fetal Medicine
does not recommend MCA-PSV
screening at all, because of the lack
of evidence that routine screening
improves perinatal outcome in
TAPS.27 This study indicated that an
advanced antenatal TAPS stage was a
significant risk factor for perinatal
mortality and severe neonatal
morbidity. Therefore, we can speculate
that a timely detection allowing ante-
natal intervention could improve theMONTH 2020outcome. Based on the mounting evi-
dence of serious effects of TAPS,19 we
suggest that to improve early detection
and possibly outcome, routine MCA-
PSV examination should be included
in the standard biweekly work-up
starting in the early second trimester.
Strengths and limitations
Caution is needed when interpreting
the findings of our study owing to the
limitations associated with retrospec-
tive study designs. Notably, this study
depended on local registrations of ter-
tiary fetal therapy centers. Therefore,
our outcome could be biased toward
severe cases of TAPS, because they are
more likely to be referred by peripheral
clinics. Furthermore, this study con-
cerned a heterogenous population,
and cases differed in GA at diagnosis,
severity of TAPS, and type of
treatment, which might have influenced
the outcome. Finally, maternal de-
mographics and comorbidities were not
elaborately studied, and therefore, the
overall risk for complications outside of
TAPS could not be taken in to account.
Nonetheless, this large international
study presents new important infor-
mation that has potential implications
for the future care of monochorionic
twins.
Conclusions
Spontaneous TAPS can occur across a
wide GA range, is managed heteroge-
neously, and is associated with high rates
of adverse perinatal outcome, particu-
larly in donor twins. Because perinatal
outcome is greatly dependent on TAPS
stage, timely detection allowing consid-
eration of antenatal treatment is of
utmost importance. To adequately
investigate the best treatment for TAPS,
an international randomized controlled
trial is needed.28 n
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(n¼249 pregnancies, 498 fetuses)
TAPS donorsa
(n¼244 fetuses)
TAPS recipientsa
(n¼244 fetuses) P value
GA at birth (wk) 32.3 (30.1e34.9; 18.7e39.6) — — —
Fetal demiseb 54/494 (11) 43/243 (18) 11/243 (5) <.001f
Spontaneous 24/494 (5) 19/243 (8) 5/243 (2) .002f
Intended 30/494 (6) 24/243 (10) 6/243 (3) <.001f
Neonatal mortalityc 18/439 (4) 11/200 (6) 7/231 (3) .161
Perinatal mortality (overall)c 72/493 (15) 54/243 (22) 18/242 (7) <.001f
Perinatal mortality (spontaneous)c 42/493 (9) 30/243 (12) 12/242 (5) <.001f
Severe neonatal morbidityd 141/432 (33) 63/196 (32) 74/228 (33) .652
Respiratory distress syndrome 118/432 (27) 51/196 (26) 64/228 (28) .413
Patent ductus arteriosus 34/432 (8) 15/196 (8) 19/228 (8) .671
Necrotizing enterocolitis 15/432 (4) 7/196 (4) 8/228 (4) .905
Retinopathy of prematurity 7/432 (2) 3/196 (2) 4/228 (2) .778
Severe cerebral injury 15/432 (4) 4/196 (2) 11/228 (5) .109
Ischemic limb injury 0/432 (0) 0/196 (0) 0/196 (0) 1.000
Birthweight (g)d 1645609 1483566 1765620 <.001f
Severe growth restriction (bw at <p3)e 126/434 (29) 98/200 (49) 26/228 (11) <.001f
Mild growth restriction (bw at <p10)e 211/434 (49) 135/200 (68) 71/228 (31) <.001f
Data are presented as meanSD medians (IQR) or n/N (%).
bw, birthweight; GA, gestational age; TAPS, twin anemia polycythemia sequence; SD, standard deviation.
a In 5 of 249 cases, the donor-recipient status was unknown; b A total of 4 missing values; c A total of 5 missing values (same as a plus 1 missing value from a liveborn recipient with unknown neonatal
mortality information); d A total of 12 missing values (same as b, plus 4 cases with unknown neonatal morbidity information and 3 cases who died shortly after birth); e A total of 9 missing values (as
in a plus 5 cases with unknown birthweights); f Statistical significance.
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SUPPLEMENTAL TABLE 1
Spontaneous TAPS cases per center
Center Country Spontaneous TAPS cases
Leiden University Medical Center The Netherlands 70
Leuven University Hospital Belgium 30
Necker-Enfants Malades Hospital, Paris France 23
Hospital Universitari Vall d’Hebron, Barcelona Spain 16
University Medical Center Hamburg-Eppendorf Germany 15
Center Medico-Chirurgical Obstetrical, Strasbourg France 13
Medical University of Graz Austria 13
Ontario Fetal Centre, Mount Sinai Hospital, University
of Toronto, Canada
Canada 12
Children’s Hospital V. Buzzi, Milan Italy 11
University of Texas McGovern Medical School at
Houston
United States of America 10
Saint George’s Hospital, London United Kingdom 9
Mater Hospital, Brisbane Australia 8
Brugmann University Hospital Belgium 7
Yale New Haven Hospital United States of America 6
Karolinska University Hospital, Stockholm Sweden 3
V.I. Kulakov National Medical Research Center of
Obstetrics, Gynecology, and Perinatology, Moscow
Russia 2
Birmingham Women’s and Children’s NHS Foundation
Trust
United Kingdom 1
TAPS, twin anemia polycythemia sequence.
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SUPPLEMENTAL TABLE 2
Univariable and multivariable risk analysis for spontaneous perinatal mortality in spontaneous twin anemia polycythemia sequence
Deatha
(n¼42/463)
Alivea
(n¼421/463)
Univariable analysis
OR (95% CI) SE P value
Multivariabled analysis
OR (95% CI) SE P value
GA at diagnosis of TAPS 22.74.8 24.75.4 0.9 (0.8e1.0) 0.05 .124
Antenatal TAPS stage
1 2/126 (2) 124/126 (98) —b
2 17/162 (11) 145/162 (89) 7.2 (1.5e32.2) 0.8 .009e 6.3 (1.4e27.8) 0.8 .016e
3 14/91 (15) 77/91 (85) 11.3 (2.5e50.5) 0.8 .002e 9.6 (2.1e45.5) 0.8 .005e
4 8/15 (35) 18/15 (65) 32.5 (5.7e186.7) 0.9 <.001e 20.9 (3.0e146.4) 1.0 .002e
Recipientc 12/236 (5) 224/236 (95) —b
Donorc 30/219 (14) 189/219 (86) 3.0 (1.7e5.4) 0.3 <.001e 3.8 (1.9e7.5) 0.3 <.001e
Antenatal therapy
Expectant management 12/101 (10) 89/101 (88) —b
Delivery 5/68 (7) 63/68 (93) 0.6 (0.2e1.8) 0.6 .334
IUT (PET) 2/52 (4) 50/52 (96) 0.3 (0.1e1.4) 0.9 .118
Laser surgery 21/163 (13) 142/163 (87) 1.1 (0.5e2.5) 0.4 .865
Selective feticide (cotwin) 2/17 (11) 17/19 (89) 0.9 (0.2e4.3) 0.8 .855
GA at birth 29.54.7 32.62.9 0.8 (0.7e0.9) 0.1 <.001 e 0.8 (0.7e0.9) 0.1 .001 e
Values are odds ratios (OR) (95% confidence intervals [CIs]), standard error (SE), and P value.
GA, gestational age; IUT, intrauterine transfusion; PET, partial exchange transfusion; SNM, severe neonatal morbidity; TAPS, twin anemia polycythemia sequence.
a A total of 30 cases were excluded as mortality occurred in context of selective feticide or termination of pregnancy, from the 648 cases 5 cases have missing values; b Set as a reference; c In 5 cases, donor-recipient status was unknown; d Antenatal TAPS stage,
donor status, and GA at birth were not correlated (antenatal TAPS stage and donor status [R<0.000; P¼.998], antenatal TAPS stage and GA at birth [R<0.001; P¼1.000], and GA at birth and donor status [R<0.000; P¼.997]), so all parameters were included in
multivariable analysis; e Statistical significance.
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SUPPLEMENTAL TABLE 3
Univariable and multivariable risk analysis for severe neonatal morbidity in spontaneous twin anemia polycythemia sequence
SNMa
(n¼141/432)
No SNMa
(n¼291/432)
Univariable analysis,
OR (95% CI) SE P value
Multivariable analysis,
OR (95% CI) SE P valueb
GA at diagnosis of TAPS 25.45.2 24.55.6 1.0 (0.9e1.0) 0.02 .300 e e e
Antenatal TAPS stage
1 40/123 (33) 83/123 (67) —
2 44/148 (30) 104/148 (70) 0.9 (0.5e1.7) 0.3 .651 0.7 (0.3e1.6) 0.4 .414
3 31/82 (38) 51/82 (62) 1.1 (0.6e2.4) 0.4 .749 1.0 (0.4e3.0) 0.5 .953
4 14/19 (74) 5/19 (26) 4.4 (1.2e16.0) 0.7 .026 7.9 (1.4e43.3) 0.8 .018e
Recipientc 74/226 (33) 153/226 (67) —b
Donorc 63/196 (32) 133/196 (68) 1.1 (0.8e1.3) 0.1 .628 — — —
Antenatal management
Expectant management 26/93 (28) 67/93 (72) —b
Delivery 32/68 (47) 35/68 (53) 2.3 (1.0e5.6) 0.4 .046 0.5 (0.1e1.5) 0.5 .252
IUT (PET) 22/50 (44) 28/50 (56) 1.9 (0.8e4.6) 0.5 .150 1.3 (0.4e4.0) 0.6 .695
Laser surgery 44/145 (31) 108/145 (69) 1.2 (0.5e2.4) 0.4 .661 1.6 (0.6e4.9) 0.6 .370
Selective feticide 4/17 (24) 13/17 (76) 0.8 (0.2e2.8) 0.6 .710 —d
GA at birth 30.12.7 33.62.3 1.7 (1.5e1.9) 0.1 <.001e 1.7 (1.5e2.1) 0.1 <.001e
Severe growth restriction, no 99/304 (33) 205/304 (67) —b
Severe growth restriction, yes 41/122 (34) 81/122 (66) 1.0 (0.7e1.5) 0.2 .842 - - -
Postnatal TAPS, no 40/156 (26) 116/156 (74) —b
Postnatal TAPS, yes 81/211 (38) 130/211 (62) 1.9 (1.0e3.3) 0.3 .039e 2.1 (0.9e5.0) 0.4 .068
There was no strong correlation between antenatal TAPS stage, antenatal management, GA at birth, and postnatal TAPS (GA at birth and postnatal TAPS [R<0.001; P¼1.000]; antenatal TAPS stage and postnatal TAPS [R¼e0.155; P¼.006]; antenatal management
[R¼e0.493; P<.001]; GA at birth and antenatal TAPS stage [R¼e0.209; P<.001]; GA at birth and antenatal management [R¼0.154; P¼.002]; antenatal management and antenatal TAPS stage [R¼0.307; P<.001]), so all were included in multivariable analysis.
Values are presented as odds ratios (OR) (95% confidence intervals [CI]), standard error (SE), and P value.
GA, gestational age; IUT, intrauterine transfusion; PET, partial exchange transfusion; SNM, severe neonatal morbidity; TAPS, twin anemia polycythemia sequence.
a A total of 12 neonates with missing neonatal outcome; b Set as a reference; c In 5 cases, donor-recipient status was unknown; d Group too small to calculate OR in multivariable analysis; e Statistical significance.
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